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Abstract 
 
Aims: This study aims to evaluate temporal changes in stroke complications and their 
association with mortality and MACE outcomes in a national cohort of patients 
undergoing percutaneous coronary interventions (PCI) in England and Wales. 
Methods and Results: 426,046 patients who underwent PCI in England and Wales 
between 2007 and 2012 in the British Cardiovascular Intervention Society (BCIS) 
database were analyzed. Statistical analyses were performed evaluating the rates of 
stroke complications according to year of PCI and multiple logistic regressions were 
used to evaluate the odds of 30-day mortality and in-hospital major adverse 
cardiovascular events (MACE; a composite of in-hospital mortality, myocardial 
infarction or re-infarction and revascularization) with stroke complications. 436 
patients (0.1%) sustained an ischaemic stroke/TIA complication and 107 patients 
(0.03%) sustained a haemorrhagic stroke complication. Ischaemic stroke/TIA 
complications increased non-linearly from 0.67(0.47-0.87) to 1.14(0.94-1.34) per 
1000 patients between 2007 and 2012 (P=0.006) whilst haemorrhagic stroke rates 
decreased non-linearly from 0.29(0.19-0.39) to 0.15(0.05-0.25) per 1000 patients in 
2012 (P=0.009). Following adjustment for baseline clinical and procedural 
demographics, ischaemic stroke was independently associated with both 30-day 
mortality (OR 4.92, 3.06-7.92) and in-hospital MACE (OR 3.11, 1.83-5.27). An even 
greater impact on prognosis was observed with haemorrhagic complications (30-day 
mortality: OR 13.87, 6.37-30.21), in-hospital MACE (OR 13.50, 6.30-28.92). 
Conclusions: Incident ischemic stroke complications have increased over time, whilst 
haemorrhagic stroke complications have decreased, driven through changes in 
clinical, procedural, drug-treatment and demographic factors. Both ischemic and 
haemorrhagic strokes are rare but devastating complications with high 30-day 
mortality and in-hospital MACE rates. 
Introduction 
 
 Both major adverse cardiovascular events (MACE) and mortality following 
percutaneous coronary intervention (PCI) have declined over the past 25-years despite 
rising patient age, increases in co-morbidity and a shift in indication from mostly 
elective to more emergent, higher risk interventions
1
. Although MACE have declined 
over time, the changes in patterns of stroke following PCI have not been fully 
described, particularly from a national perspective. Incident stroke rates have been 
reported between 0.1-0.6% in single-centre and other national registry data
2-7
. 
Stroke as a complication of PCI is associated with high in-hospital mortality 
rates
6-8
 and potentially causes significant and devastating life changing disabilities in 
surviving patients
5,9,10
. The stroke complications of PCI can be ischaemic or 
haemorrhagic
10
. Guide catheter manipulation within the aortic arch or use of 
circulatory support devices during PCI can cause embolization of atherosclerotic 
material from the aorta leading to ischaemic stroke complications
11
 and an ageing 
population undergoing PCI with high prevalences of co-morbid conditions further 
increases the risk of stroke complications during PCI
6
. In addition, use of potent 
antiplatelet and anti-coagulant therapies during PCI increases the risk of 
haemorrhagic stroke in such patients. 
 Previous large-scale studies (e.g. from the Euro Heart Survey Percutaneous 
Coronary Interventions survey
7
 and the National Cardiovascular Data Registry 
(NCDR) from North America
6
 have studied the incidence, major determinants and 
outcomes of stroke following PCI. These studies, however, have not differentiated 
between ischaemic and haemorrhagic mechanisms, nor have they looked at temporal 
changes, which is especially important given the changing indications for PCI and its 
application to an older population. Whilst more detailed study from single centres is 
enlightening
1,4
 these studies may not be generalizable as the observations relate to a 
specific case-mix and local procedural practice. 
 We have therefore studied the temporal changes in haemorrhagic and 
ischaemic stroke in an unselected cohort of patients undergoing PCI in England and 
Wales through analysis of the British Cardiovascular Intervention Society (BCIS) 
database. We report the clinical and procedural predictors of both types of stroke and 
their associated mortality and MACE outcomes. 
 
Methods 
The British Cardiovascular Intervention Society Database 
 The British Cardiovascular Intervention Society (BCIS) collects data on all 
PCI procedures in the UK. The data collection is coordinated by the National Institute 
of Cardiovascular Outcomes Research (www.ucl.ac.uk/nicor) via the Central Cardiac 
Audit Database. In 2011, this dataset collected information on 99% of all PCI 
procedures performed in National Health Service Hospitals in England and Wales. 
 The BCIS-NICOR database contains a total of 113 variables, which includes 
information on clinical variables, procedural parameters and patient outcomes. 
Mortality tracking is undertaken by the Medical Research Information Service 
(MRIS) using patients’ NHS number that provides a unique identifier for any person 
registered with the NHS in England and Wales. Mortality tracking was not possible in 
this study for patients from Scotland or Northern Ireland. 
 
Study definitions 
 We analysed all patients who underwent PCI in the UK between 1 January 
2007 and 31 December 2012. Patients were classified into three groups: i) patients 
with no in-hospital stroke complications, ii) ischaemic stroke or transient ischaemic 
attack (TIA) in-hospital complication and iii) haemorrhagic stroke complication. The 
main outcomes that were examined were 30-day mortality and in-hospital major 
adverse cardiovascular events. Major adverse cardiovascular events were defined as 
the composite of in-hospital mortality, myocardial infarction or re-infarction and 
revascularization (emergency coronary artery bypass graft or re-intervention PCI). 
 Additional data were collected on baseline variables including year of 
procedure, age, gender, smoking status, comorbidities (diabetes, hypertension, 
hyperlipidaemia, previous myocardial infarction, previous stroke, peripheral vascular 
disease, chronic renal disease and previous valve disease), previous PCI, previous 
coronary artery bypass graft, access site, cardiogenic shock, use of circulatory 
support, thrombus aspiration, use of ventilatory support, revascularization of the left 
main stem, indication/diagnosis (stable angina, NSTEMI, STEMI) and medications 
received (any glycoprotein IIb/IIIa inhibitor, aspirin, clopidogrel, prasugrel, 
ticagrelor, ticlopidine and warfarin use). 
 
 
 Statistical analysis 
 Statistical analyses were performed using Stata/MP version 13 (Stata Corp, 
TX, USA) and StatsDirect version 3 (StatsDirect Ltd, UK). 
 Summary statistics were expressed as means and standard deviations for 
continuous variables, and percentages for categorical variables. Comparisons of 
means were made using t-tests and one-way analyses of variance, with appropriate 
consideration of multiple testing for pairwise contrasts of the three main groups. 
Proportions were compared using Fisher’s method for fourfold tables and chi-square 
(with simulated exact P-values) linear trend tests for ordinal series. We excluded 
patients with missing values for age, mortality at 30 days, MACE and stroke 
complications. A flow diagram graphically describes how the final cohort was derived 
(Figure 1). 
 We present descriptive statistics of baseline variables by complication group 
in Table 1. We graphically examined the rates of ischaemic stroke or TIA and 
haemorrhagic stroke over time (Figure 2). Simple logistic regressions were used to 
investigate the effect of each baseline variable as a potential predictor of ischaemic 
stroke or TIA and haemorrhagic stroke. Multiple logistic regressions, in which all 
baseline variables and year of PCI were included in the two models, were used to 
identify predictors of: i) ischaemic stroke or TIA; and ii) haemorrhagic stroke. 
 The primary outcomes were 30-day mortality and in-hospital MACE. Multiple 
logistic regressions were used to investigate the effect of each neurological 
complication on 30-day mortality and in-hospital MACE rates, using both unadjusted 
and adjusted for baseline variables models. The final adjusted models were controlled 
for all collected baseline variables and year of PCI. Chained equations multiple 
imputations (using mi impute chained in Stata) were used to generate 10 complete 
datasets with imputed data for missing baseline variables. Additional sensitivity 
analyses were ran in which we tried to better control for covariates. Under a similar 
multiple imputation setting, we calculated the propensity scores for membership on 
each group in the comparisons we investigated, using all available covariates. Using 
the aggregate patient propensity score across all 10 multiple imputation datasets, we 
then matched each ‘case’ (e.g. TIA only) to up to 10 ‘controls’ (e.g. no TIA) with 
scores within 10
-5
. 
 Cases with missing data that were excluded from the analyses were compared 
to cases that were included in the final analysis, for baseline variables and outcomes 
(when available) (Supplementary Table 1). Results are presented as the main effect 
with 95% confidence interval unless otherwise stated. 
 
Results 
  
 A total of 438,400 patients underwent PCI in England and Wales and 426,297 
patients were included in the analysis after exclusion of participants with missing 
values for mortality at 30 days, and stroke outcomes. Figure 1 shows the process of 
patient inclusion. A comparison of patient characteristics for included participants and 
excluded participants is shown in Supplementary Table 1. Supplementary Table 2 and 
3 shows missing data for each variable and by year of procedure. Many of the 
characteristics compared showed statistically significant differences between those 
included in the study and the 12,103 patients excluded for the analysis although there 
were no material differences in stroke risk factors such as age, previous CVA, 
diabetes, hypertension and 30 day mortality outcomes were similar. 
 A total of 543 (0.13%) patients experienced an in-patient stroke complication 
following PCI of which 436 patients (0.1%) sustained an ischaemic stroke 
complication and 107 patients (0.03%) sustained a haemorrhagic stroke complication. 
The rates of ischaemic stroke/TIA and haemorrhagic stroke according to year of PCI 
are shown in Figure 2. Ischaemic stroke/TIA complications increased non-linearly 
from 0.67(0.47-0.87) to 0.114(0.094-0.134) per 1000 patients between 2007 and 2012 
(P=0.006) whilst haemorrhagic stroke rates decreased non-linearly from 0.29(0.19-
0.39) to 0.15(0.05-0.25) per 1000 patients in 2012 (P=0.009) (Supplementary table 4). 
Interestingly TIA rates remained similar over the study period from 0.34 (0.24-0.44) 
per 1000 patients in 2007 to 0.39 (0.29-0.49) in 2012, whilst ischaemic stroke rates 
increased from 0.33 (0.23-0.43) per 1000 patients in 2007 to 0.75 (0.55-0.95) in 2012.  
 Clinical and procedural demographics are presented in Table 1. Patients who 
experienced ischaemic stroke complications or TIA following PCI were older, more 
likely to have a previous history of stroke, more likely to be female, have valvular 
heart disease and were more likely to present as non-elective cases compared to those 
patients that did not experience cerebrovascular complications. Similarly, patients 
with haemorrhagic stroke complications were more likely to be older, female, 
undergo PCI for non-elective indications and be more haemodynamically unstable as 
evidenced by the increased rates of cardiogenic shock and circulatory support in this 
group. Furthermore, Patients with haemorrhagic strokes were more likely to have 
been treated with warfarin, thrombolysis and glycoprotein IIb/III inhibitors. 
 30-day mortality rate was 8,597/425,503 (2.0%) in the control group, 70/436 
(16%) in the group of patients who experienced an ischaemic stroke /TIA and 51/107 
(48%) for the cohort of patients who experienced a haemorrhagic stroke complication. 
Similar rates of MACE were observed across the groups. Supplementary table 5 
presents crude mortality and MACE rates for the stroke / TIA cohort separate into 
separate ischaemic stroke and TIA groups. 30-day mortality was 55/261 (21%) in 
patients who sustained ischemic stroke complications and 15/175 (9%) in patients 
with TIA complications. 
 Simple and multiple logistic regression, (in the latter adjusting for all baseline 
clinical and procedural demographics) was performed to identify predictors of both 
ischaemic stroke/TIA and haemorrhagic stroke complications (Tables 2 and 3). After 
adjustments for baseline variables, factors independently associated with increased 
odds of ischaemic stroke/TIA included age, previous stroke, female gender, valvular 
heart disease, receipt of circulatory support, thrombus aspiration and diagnosis of 
NSTEMI and STEMI (Table 3). For haemorrhagic stroke complications, independent 
predictors following adjustment for baseline covariates included age, valvular heart 
disease, diagnosis of NSTEMI or STEMI, receipt of thrombolysis and warfarin use 
(Table 3). 
 In order to study how changes in clinical and procedural demographics have 
contributed to the changes in the incidence of both ischemic (increase) and 
haemorrhagic (decrease) stroke rates over time, we have presented how predictors of 
both stroke types have varied over time (Table 4). The average age of the cohort, use 
of circulatory support devices, prevalence of patients with valvular heart disease or a 
previous history of stroke, and procedures undertaken for STEMI indications have all 
increased over time, which would contribute to the increased incidence of ischaemic 
stroke event rates observed. In contrast, whilst the prevalence of warfarin use and 
valvular heart disease, average age and procedures undertaken for STEMI indications 
have increased over time, which would contribute to an increased incidence of 
haemorrhagic stroke, there has been a major decrease in thrombolysis (from 9.26% in 
2007 to 1.16% in 2012; P<0.001) that would tend to reduce incident haemorrhagic 
stroke complications. 
 We investigated the association between stroke complications and adverse 
outcomes (Table 5). An ischaemic stroke complication (or TIA) was associated with a 
9-fold increased odds of 30-day mortality (OR 9.27, 7.18-11.99) and an 8-fold 
increased odds of in-hospital MACE (OR 8.34, 6.48-10.73). Following adjustment for 
baseline clinical and procedural demographics, ischaemic stroke remained 
independently associated with both 30-day mortality (OR 4.94, 3.07-7.93) and in-
hospital MACE (OR 3.13, 1.84-5.30). Supplementary Table 6 separates the 
prognostic impact of TIA and ischaemic stroke complications on 30-day mortality and 
in-hospital MACE and demonstrates that both Stroke and TIA complications 
independently predicted MACE (OR 3.16 95% 1.65-6.07 and OR 3.07 95% CI 1.26-
7.48) and 30-day mortality (OR 4.79 95 % CI 2.68-8.57 and OR 5.24 95% CI 2.32-
11.81). 
 An even greater impact on prognosis was observed with haemorrhagic 
complications, with up to a 40-fold increase in odds of 30-day mortality (OR 44.2, 
30.2-64.6) and MACE (OR 37.8, 25.82-55.20). Even after adjustment for baseline 
covariates, this relationship persisted (30-day mortality: OR 13.83, 6.35-30.12), in-
hospital MACE (OR 13.19, 6.15-28.30). 
In order to reduce the influence of unmeasured confounders on outcomes, a 
propensity score matched cohort was generated (propensity score difference below 
10
-5
). The logistic regression results with multiple imputation in the propensity-
matched cohort are shown in Table 6. Both ischaemic stroke / TIA and haemorrhagic 
stroke were associated with increased odds of 30-day mortality (OR 2.66 95% CI 
1.97-3.60 and OR 4.08 95% CI 2.61-6.38 respectively) and in-hospital MACE (OR 
2.54 95% CI 1.88-3.42 and OR 3.83 95% CI 2.45-5.98 respectively). When ischaemic 
stroke and TIA were studied separately, the increased odds of 30-day mortality 
remained significant for both an ischaemic stroke (OR 2.79 95% CI 1.96-3.97; 
P<0.001) and TIA (OR 1.85 95% CI 1.02-3.35; P=0.042). For completeness, we 
present the propensity scores within each group in Supplementary Table 7. 
 
 
Discussion 
 In one of the largest population-based case-cohort analyses published to date, 
we have shown that the incidence of ischemic stroke complications in contemporary 
PCI practice is 3-fold greater than that of haemorrhagic stroke. Ischaemic stroke 
complications have increased in incidence over time, whilst haemorrhagic stroke 
complications have decreased, driven through temporal changes in clinical, 
procedural, drug-treatment and demographic factors. Furthermore, we demonstrate 
that both ischemic and haemorrhagic strokes are rare but have devastating 
complications with high 30-day mortality and in-hospital MACE rates, with 
ischaemic stroke independently associated with a 5-fold increased odds and 
haemorrhagic stroke with a 14-fold increase in odds of 30-day mortality post PCI. 
 Our data show an incident in-hospital stroke rate of 0.13% in our unselected 
national cohort of patients undergoing PCI, with a 3-fold greater incidence of 
ischaemic strokes compared to haemorrhagic strokes. Studies such as the SYNTAX 
study have reported incident stroke rates of 0.2% at 30-days
12
 with the ACUITY trial 
reporting rates of up to 0.3%
13
, whilst national registries such as the NCDR and 
international registries such as the EuroHeart survey have reported stroke rates 
between 0.2 and 0.4% respectively
6,7
. Other, single centre, registry studies have 
reported rates of between 0.15 - 0.4%
3,4
. Incident stroke rates will depend on the 
clinical characteristics of the cohort studied, with a 2-fold greater incidence reported 
in patients undergoing PCI for ACS indications compared to the elective setting in the 
EuroHeart survey
7
. 
 To the best of our knowledge, our analysis is the first to systematically study 
haemorrhagic and ischemic stroke complications separately following PCI from a 
large scale national perspective, with such data either not being available for analysis 
in previous reports derived from the NCDR
6
 or not presented in the EuroHeart 
survey
7
. In a single centre study of Hoffman et al undertaken at the Mayo clinic that 
reported incident stroke complications of 0.37%, 90% of all stroke complications 
were ischemic in origin whereas 7% were reported as haemorrhagic strokes
4
, although 
predictors, outcomes and changes in incidence over time were not studied separately 
for each sub-type of stroke. 
 We have observed that incident stroke rates have increased over a 6-year 
timeframe in England and Wales, which has been driven by an increase in incident 
ischemic stroke complications, whereas haemorrhagic stroke rates have decreased 
over a similar time frame. Whilst changes in incident stroke have not been previously 
reported from a national perspective, single centre studies report varying results with 
both significant and non-significant decreases
14
 and non-significant increases in 
stroke rates over time
3
. In the Swedish heart intensive care admission registry
15
, 
haemorrhagic strokes were reported to decrease by over 50% over a 10-year period in 
acute myocardial infarction, driven largely through changes in thrombolysis practice, 
although in those patients who underwent primary PCI, rates of haemorrhagic strokes 
remained relatively stable over time. 
 We have identified a number of independent predictors of ischaemic stroke 
complications such as female gender, increasing age, prevalent valvular heart disease, 
a previous history of stroke, use of circulatory support devices and PCI in the setting 
of both NSTEMI and STEMI. Similarly, previous analyses have also identified 
female gender
4,6,7
, previous stroke history
3,4
, age
4,6,7,13,14
, circulatory support 
devices
6,14
, thrombus containing lesions
3
 and PCI for ACS indications
4,6,14
 as 
independent predictors of stroke complications. Our analysis suggests that the 
presence of valvular heart disease is amongst the strongest predictors of ischaemic 
stroke complications. Similarly, the smaller euro heart registry consisting of 46,888 
patients has documented that prevalent valvular heart disease is associated with a 2-
fold increase in stroke risk although this did not reach statistical significance
7
. The 
BCIS dataset does not differentiate between native valvular heart disease and its 
severity, and prosthetic valves that might increase risk of thrombotic embolisation and 
ischaemic stroke complications, particularly if anti-coagulants have been discontinued 
for the PCI procedure. In addition, valvular heart disease such as aortic stenosis
16
 and 
mitral valve disease
17
 are well-described independent predictors of stroke risk. Finally 
the presence of valvular heart disease may be a surrogate for prevalent atrial 
fibrillation that is unrecorded in the BCIS dataset that would in itself increase stroke 
risk. 
 Our analysis suggests that the observed increase in incident ischemic stroke 
complications over time may relate to temporal changes in patient demographics and 
PCI practice. The average age of the cohort has increased over time, along with the 
prevalence of valvular heart disease, history of stroke, ACS indications for PCI and 
increases in circulatory support device use over time that would all contribute to the 
increases in stroke rates reported. 
 We identify both a number of shared risk factors such as age, ACS indications 
for PCI and valvular heart disease as important independent predictors of 
haemorrhagic stroke complications as well as additional risk factors such as warfarin 
use and thrombolysis that are independent predictors for only haemorrhagic strokes. 
We also identify GPIIb/IIIa and haemodynamic instability such as cardiogenic shock 
presentation, receipt of ventilatory or circulatory support as uni-variate predictors of 
haemorrhagic stroke. Whilst age, thrombolysis and warfarin use are recognised risk 
factors for haemorrhagic strokes, the mechanism through which the presence of 
valvular heart disease independently predicts stroke is not clear. Valvular heart 
disease may be a surrogate for anticoagulant use, that may not have been fully 
captured in the BCIS dataset, both from the perspective of anti-coagulant for 
thromboprophylaxis for atrial fibrillation (that is associated with prevalent valvular 
heart disease) and for prosthetic heart valves. Changes in both platelet physiology 
18
 
and coagulation pathways
19
 are well documented in cardiogenic shock that might 
contribute to the increased haemorrhagic complications observed in cardiogenic shock 
on univariate analysis
20
. 
 It is of interest that we have identified ACS indications for PCI as independent 
predictors for both ischemic and haemorrhagic stroke complications, analogous to the 
observation that both STEMI and NSTEMI are strong independent predictors of both 
stent thrombosis
21
 and major bleeding complications
22
 during PCI which may relate to 
increased thrombus burden in lesions treated for ACS indications, higher anti-platelet 
reactivity hence the requirement for more aggressive antiplatelet and anti-coagulant 
regime use. Similarly, prevalent valvular heart disease is a strong independent 
predictor of both ischaemic and haemorrhagic stroke complications. As described, 
patients with prevalent valvular heart disease within the BCIS database are a 
heterogeneous cohort of patients consisting of patients with native valvular heart 
disease of varying severity and patients with prosthetic heart valves. These patients 
with prevalent valvular heart disease will have a significant prevalence of atrial 
fibrillation that is not captured in the BCIS dataset and a significant proportion of 
such patients will be anti-coagulated both for thromboprophylaxis against AF as well 
as for prosthetic heart valves. This heterogeneous cohort of patients will have 
important risk factors for both haemorrhagic and ischaemic stroke complications 
hence the importance of valvular heart disease as a predictor of both haemorrhagic 
and ischemic stroke complications. 
 It is likely that competing risks contribute overall to the observed decline in 
haemorrhagic stroke rates over time. Some of the independent predictors of 
haemorrhagic stroke have increased in prevalence over time such as warfarin use, 
valvular heart disease, STEMI PCI and average age which would tend to favour an 
increase in haemorrhagic strokes whilst other important independent predictors such 
as thrombolysis have declined over time, which reflect changes in PCI practice 
particularly with a move from rescue PCI, facilitated PCI or PCI following successful 
thrombolysis in STEMI towards primary PCI more recently. Indeed, in the Swedish 
heart intensive care admission registry
15
, haemorrhagic strokes were reported to 
decrease by over 50% over a 10-year period in acute myocardial infarction, driven 
largely through changes in thrombolysis practice. 
 Our analysis suggests that stroke complications independently predict adverse 
mortality and MACE outcomes, and that haemorrhagic stroke complications are 
independently associated with a 10–fold increased odds of 30-day mortality, whilst 
ischemic stroke complications increase this 4-fold. Whilst most previous studies have 
not reported the prognostic impact of stroke complications according to whether the 
aetiology is ischaemic or haemorrhagic, stroke was associated with a 12-fold 
unadjusted increase in in-hospital mortality and a 10-fold increase in MACE in the 
EuroHeart registry
7
. Similarly data derived from the ACUITY trial has reported 
unadjusted 8-fold increases in 30 day mortality and 2.4 fold increases in MACE 
events following stroke
13
. In a patient-level pooled analysis of the 7 ISAR trials, 
intracranial bleeding was associated with a 22-fold unadjusted increase risk in 1-year 
mortality, although this data was based on a total of 9 intra-cranial bleeding events
23
. 
These observations are in keeping with our reported unadjusted rates of 9-fold 
increase in 30-day mortality for ischemic strokes and 44-fold increase for 
haemorrhagic strokes. Indeed in an analysis undertaken at the Mayo clinic in which 
cause of death was studied in patients undergoing PCI over a 17-year period, stroke 
events accounted for 6% of all mortalities during this period of time
24
 whilst another 
single centre study has suggested that neurological complications contribute to 15% 
of mortalities post PCI
25
. We have also attempted to separate the prognostic impact of 
ischaemic strokes and TIA and shown that both TIA and stroke are independently 
associated with increased odds of 30-day mortality and MACE in our main analysis 
and propensity score matching. Interestingly, when the impact of stroke versus TIA 
on one-year all-cause mortality was separately considered in an analysis of the Acuity 
trial, mortality was significantly increased after the occurrence of stroke (HR 4.16, 
95% CI [2.13, 8.13], p<0.001) but not after TIA (HR 1.52, 95% CI [0.21, 10.83], 
p=0.68) although this may have been limited by the statistical power of this analysis 
as evidenced by the wide confidence intervals.
13
 Finally, whilst we have attempted to 
adjust for differences in baseline covariates between patients who sustained stroke 
complications and those who did not, and attempted to reduce the influence of the 
potential confounders through the use of propensity score matching, our association 
between stroke complications and increased odds of mortality and MACE outcomes 
does not infer a causal relationship, but maybe driven by unmeasured confounders or 
unrecorded measures of frailty. 
Whilst the absolute 30-day mortality rates for ischaemic and haemorrhagic 
strokes of 16 and 48% respectively are striking, even those patients that survive 
would have significant life changing disabilities, for example in the SYNTAX study, 
close to 60% of patients who experienced a stroke complication and survived were 
left with residual neurological deficits post hospital discharge
12
. Similarly, in the 
single centre analysis of Dukkipati et al
14
, 70% of patients who survived the stroke 
were left with significant neurological deficit with skilled home care needed in 26% 
of patients, nursing home or assisted living in 9%, and inpatient rehabilitation in 22%. 
Our group has previously reported in an analysis of over 3000 community patients 
admitted with stroke in England, similar 30-day mortality rates to those reported here, 
with 18% 30-day mortality for ischaemic strokes and 42% mortality for haemorrhagic 
strokes
26
, suggesting that the adverse outcomes associated with stroke complications 
following PCI are similar to those observed in the community. Whilst community 
stroke registries have suggested that haemorrhagic strokes account for around 15% of 
all strokes in the UK
26-28
, haemorrhagic strokes account for 25% in our analysis, 
which may relate to the potent drug therapies used in PCI that predispose to 
haemorrhagic complications. 
Our study has several strengths. The BCIS dataset includes >95% of all PCI 
procedures performed in the United Kingdom which therefore reflects a national, real-
world experience that includes high-risk patients encountered in daily interventional 
practice who are often excluded from randomized controlled trials. In our current 
analysis, we have studied neurovascular complications in over 400,000 patients and as 
such this analysis represents the one of the largest analyses of changes in incident 
neurovascular complications over time and due to its size is able to: capture relatively 
rare complications of PCI; and for the first time from a national perspective, 
systematically study changes, predictors and outcomes of both ischaemic and 
haemorrhagic stroke complications. 
 There are some limitations in this study, which are worth highlighting. Our 
dataset does not capture the timing of the stroke complications. Furthermore, the 
BCIS dataset does not provide information regarding the neurological deficit 
sustained following a stroke. In the study of Dukkipati et al. the 3 most common 
neurological manifestations were motor (35%), speech (33%) and mental state 
changes (32%) 
14
 whilst in the study of Hoffman the most frequently occurring 
clinical features were limb motor weakness (49%), speech impairment (39%), visual 
disturbance (20%), and facial droop (18%) and unresponsiveness was present in 12% 
4
. Similar to previous large national and multi-national studies, BCIS does not record 
prevalent atrial fibrillation (AF), which is a similar limitation encountered in both 
analysis derived from the EuroHeart Survey
7
 and NCDR dataset
6
. Nevertheless, 
whilst AF contributes to about 15% of ischaemic strokes and is hence one of the most 
important predictors stroke in the community setting
29,30
, the role of AF as a risk 
factor for stroke following PCI has not been widely studied. Our analysis suggests 
that valvular heart disease is one of the most powerful predictors of ischemic stroke 
events that may be a surrogate marker for incident AF. Interestingly in one analysis 
where prevalent AF data was recorded, whilst AF was more common in patients who 
sustained a stroke complication following PCI, prevalent AF did not independently 
increase risk of stroke in this setting 
3
. 
 Thirdly, diagnosis of stroke is self-reported by individual operators with no 
external validation hence there is the potential for under-reporting of neurological 
events, although our reported incident stroke rates are similar in magnitude to those 
reported in the national NCDR
6
 and the SCAAR
31
 datasets derived from USA and 
Sweden respectively. 
 Finally, our analysis reports in-hospital stroke events that may represent 
periods of only a few hours of time for day case procedures or a few days for other 
inpatient cases. Previous findings from a single centre data suggest that 60% of 
strokes occur within 24 hours and 20 % between 24-48 hours with the remaining 
events occurring after 48 hours
14
 that may explain differences in reported stroke rates 
in our analysis and those reported in randomised trials that report stroke events upto 
30-days post index procedure
12,13
. 
 In conclusion, we have shown that the incidence of ischemic stroke 
complications in contemporary PCI practice is 3-fold greater than that of 
haemorrhagic stroke, with ischemic stroke complications increasing in incidence over 
time, whilst haemorrhagic stroke complications have decreased, and that these 
changes in incident rates have been driven through changes in clinical, procedural, 
drug-treatment and demographic factors over time. Furthermore, we confirm that both 
ischemic and haemorrhagic strokes are rare but devastating complications with high 
30-day mortality and in-hospital MACE rates. 
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Figure Legends 
Figure 1: Flow chart of participant inclusion 
 
Figure 2: Rates of stroke/transient ischaemic attack and haemorrhagic stroke 
complications according to year of PCI 
Caption for Figure 2: Changes in the rates (per 1000 patients) of ischaemic stroke / 
TIA complications and haemorrhagic stroke complications over time (2007-2012). 
Error bars represent 95% confidence intervals. 
Table 1: Patient characteristics contrasting stroke types with no stroke 
Variable No stroke 
(n=425,503) 
Ischaemic 
stroke (n=436) 
P-
value 
Haemorrhagic 
stroke (n=107) 
P-
value 
Age 65 (±12) 71 (±12) <0.001 69 (±11) <0.001 
Female gender 110,568/424,622 
(26%) 
157/436 (36%) <0.001 42/107 (39%) 0.003 
Smoking 
(current or ex 
smoker) 
241,845/373,796 
(65%) 
247/391 (63%) 0.53 58/94 (62%) 0.59 
Diabetes 76,767/406,931 
(19%) 
81/431 (19%) 1.00 22/104 (21%) 0.53 
Hypertension 219,550/415,737 
(53%) 
238/432 (55%) 0.36 59/106 (56%) 0.63 
Hyperlipidaemia 232,720/415,737 
(56%) 
230/432 (53%) 0.27 51/106 (48%) 0.12 
Previous MI 106,856/379,338 
(28%) 
107/392 (27%) 0.74 28/99 (28%) 1.00 
Previous CVA 14,991/415,737 
(3.6%) 
45/432 (10%) <0.001 10/106 (9.4%) 0.008 
Peripheral 
vascular disease 
19,726/415,737 
(4.7%) 
36/432 (8.3%) 0.001 10/106 (9.4%) 0.035 
Renal disease 10,785/402,954 
(2.7%) 
12/421 (2.9%) 0.76 5/100 (5.0%) 0.20 
Previous 
valvular heart 
disease 
4,650/425,499 
(1.1%) 
45/436 (10.3%) <0.001 34/107 (32%) <0.001 
Previous PCI 90,515/408,153 
(22%) 
71/432 (16%) 0.004 24/104 (23%) 0.81 
Previous CABG 34,333/407,114 
(8.4%) 
35/425 (8.2%) 1.00 6/103 (5.8%) 0.48 
Access site 
Femoral 
Radial 
 
225,748 (56%) 
177,149 (44%) 
 
212 (52%) 
199 (48%) 
0.073  
76 (77%) 
23 (23%) 
<0.001 
Cardiogenic 
shock 
8,036/397,267 
(2.0%) 
33/425 (7.7%) <0.001 19/102 (19%) <0.001 
Use of 
circulatory 
support 
8,336/395,144 
(2.1%) 
39/426 (9.2%) <0.001 18/105 (17%) <0.001 
Thrombus 
aspiration  
45,873/397,263 
(12%) 
117/421 (28%) <0.001 25/106 (24%) 0.001 
Ventilatory 
support 
4,887/355,239 
(1.3%) 
21/387 (5.4%) <0.001 10/97 (10%) <0.001 
Left main stem 
revascularization 
13,138/411,575 
(3.2%) 
20/431 (4.6%) 0.098 8/106 (7.5%) 0.021 
Diagnosis 
Stable angina 
NSTEMI 
STEMI 
 
172,553 (41%) 
157,582 (38%) 
88,815 (21%) 
 
84 (19%) 
153 (35%) 
197 (45%) 
<0.001  
17 (16%) 
30 (28%) 
60 (56%) 
<0.001 
Glycoprotein 88,024/372,657 144/400 (36%) <0.001 45/102 (44%) <0.001 
IIb/IIIa (24%) 
Aspirin 329,975/394,968 
(84%) 
354/414 (86%) 0.32 82/101 (81%) 0.50 
Clopidogrel 304,885/394,968 
(77%) 
317/414 (77%) 0.77 81/101 (80%) 0.55 
Prasugrel 13,465/394,968 
(3.4%) 
25/414 (6.0%) 0.006 2/101 (2.0%) 0.59 
Ticagrelor 2,782/394,968 
(0.7%) 
1/414 (0.2%) 0.38 0/101 (0%) 1.00 
Ticlopidine 1,362/394,968 
(0.3%) 
2/414 (0.5%) 0.66 0/101 (0%) 1.00 
Warfarin 3,779/394,968 
(1.0%) 
8/414 (1.9%) 0.067 3/101 (3.0%) 0.074 
Thrombolysis 18,680/385,407 
(4.8%) 
18/409 (4.4%) 0.68 27/106 (25%) <0.001 
30-day mortality 8,597/425,503 
(2.0%) 
70/436 (16%) <0.001 51/107 (48%) <0.001 
MACE 10,022/425,503 
(2.4%) 
73/436 (17%) <0.001 51/107 (48%) <0.001 
 
Table 2:Univariate baseline predictors of ischaemic stroke/transient ischaemic attack and haemorrhagic stroke 
 
Variable Ischaemic stroke or transient 
ischaemic attack 
Haemorrhagic stroke 
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
Age 1.05 (1.04-1.06) <0.001 1.03 (1.02-1.05) <0.001 
Male gender 0.63 (0.51-0.76) <0.001 0.55 (0.37-0.80) 0.002 
Current smoker 0.94 (0.76-1.15) 0.527 0.88 (0.58-1.33) 0.544 
Diabetes 1.00 (0.78-1.27) 0.970 1.15 (0.72-1.85) 0.551 
Hypertension 1.10 (0.91-1.33) 0.342 1.12 (0.76-1.65) 0.557 
Hyperlipidaemia 0.90 (0.74-1.08) 0.252 0.73 (0.50-1.07) 0.104 
Previous MI 0.96 (0.77-1.20) 0.701 1.01 (0.65-1.56) 0.980 
Previous CVA 2.91 (2.13-3.96) <0.001 2.60 (1.35-4.99) 0.004 
Peripheral vascular 
disease 
1.83 (1.30-2.57) 0.001 2.09 (1.09-4.01) 0.027 
Renal disease 1.07 (0.60-1.89) 0.825 1.91 (0.78-4.70) 0.157 
Previous valvular 
heart disease 
10.42 (7.64-14.20) <0.001 41.79 (27.79-62.84) <0.001 
Previous PCI 0.69 (0.54-0.89) 0.004 1.05 (0.67-1.66) 0.824 
Previous CABG 0.97 (0.69-1.38) 0.883 0.67 (0.29-1.53) 0.344 
Radial access 1.20 (0.99-1.45) 0.070 0.39 (0.24-0.61) <0.001 
Cardiogenic shock 4.08 (2.86-5.82) <0.001 11.05 (6.71-18.21) <0.001 
Use of circulatory 
support 
4.68 (3.36-6.50) <0.001 9.57 (5.76-15.90) <0.001 
Thrombus aspiration  2.95 (2.38-3.65) <0.001 2.36 (1.51-3.70) <0.001 
Ventilatory support 4.11 (2.65-6.39) <0.001 8.21 (4.27-15.81) <0.001 
Left main stem 
revascularization 
1.48 (0.94-2.31) 0.089 2.47 (1.20-5.09) 0.014 
Diagnosis  <0.001   
NSTEMI 
STEMI 
1.99 (1.53-2.60) 
4.56 (3.53-5.88) 
1.93 (1.07-3.50) 
6.85 (3.99-11.73) 
0.030 
<0.001 
Glycoprotein 
IIb/IIIa 
1.82 (1.48-2.23) <0.001 2.55 (1.73-3.77) <0.001 
Aspirin 1.16 (0.88-1.53) 0.282 0.85 (0.52-1.40) 0.523 
Clopidogrel 0.97 (0.77-1.21) 0.763 1.20 (0.73-1.95) 0.472 
Prasugrel 1.82 (1.21-2.73) 0.004 0.57 (0.14-2.32) 0.434 
Ticagrelor 0.34 (0.05-2.43) 0.283 No events - 
Ticlopidine 1.40 (0.35-5.63) 0.633 No events - 
Warfarin 2.04 (1.01-4.11) 0.046 3.17 (1.00-9.99) 0.049 
Thrombolysis 0.90 (0.56-1.45) 0.68 6.71 (4.33-10.39) <0.001 
Year 1.11 (1.05-1.17) <0.001 0.84 (0.75-0.94) 0.003 
 
 
Table 3: Independent predictors of ischaemic stroke/transient ischaemic attack and haemorrhagic stroke 
 
Significant predictors of ischaemic stroke or transient ischaemic attack (n=238,707) 
Variable Odds ratio (95% CI) P-value 
Age 1.05 (1.04-1.06) <0.001 
Male gender 0.68 (0.53-0.87) 0.002 
Previous stroke 1.88 (1.27-2.78) 0.002 
Previous valvular heart disease 4.48 (2.87-7.00) <0.001 
Receipt of circulatory support 1.71 (1.03-2.84) 0.038 
Thrombus aspiration 1.64 (1.19-2.27) 0.003 
Diagnosis of NSTEMI 1.84 (1.30-2.61) 0.001 
Diagnosis of STEMI 2.88 (1.92-4.33) <0.001 
Significant predictors of haemorrhagic stroke (n=225,708) 
Variable Odds ratio (95% CI) P-value 
Age 1.03 (1.00-1.05) 0.024 
Previous valvular heart disease 21.30 (10.73-42.28) <0.001 
Diagnosis of NSTEMI 3.24 (1.19-8.79) 0.021 
Diagnosis of STEMI 5.50 (1.91-15.85) 0.002 
Warfarin use 4.47 (1.33-15.02) 0.015 
Thrombolysis 4.02 (2.18-7.39) <0.001 
 
Variables in adjusted model: age, gender, smoker, diabetes, hypertension, hypercholesterolaemia, thrombolysis, previous myocardial infarction, 
previous stroke, peripheral vascular disease, valvular heart disease, previous PCI, previous CABG, cardiogenic shock, receipt of circulatory 
support, thrombus aspiration, receipt of ventilation, left main stem PCI, diagnosis of NSTEMI, diagnosis of STEMI, receipt of glycoprotein 
IIb/IIIa inhibitor use, aspirin use, clopidogrel use, prasugrel use, ticagrelor use, ticlopidine use and warfarin use. 
 
 
Table 4: Exploration of how significant predictors of ischaemic and haemorrhagic stroke complications change over time* 
Variable 2007 2008 2009 2010 2011 2012 p-value 
Ischaemic stroke 
Age (95% CI) 64.20 (64.11-
64.29) 
64.40 (64.31-
64.49) 
64.90 (64.81-
64.99) 
64.90 (64.81-
64.99) 
65.20 (65.11-
65.29) 
65.10 (65.02-
65.18) 
<0.001 
Male gender 
(%, 95% CI) 
45,250/61,191 
(73.95, 73.60-
74.30%) 
49,014/66,194 
(74.05, 73.72-
74.38%) 
52,129/70,531 
(73.91, 73.59-
74.23%) 
53,975/72,940 
(74.00, 73.68-
74.32%) 
55,713/75,356 
(73.93, 73.62-
74.24%) 
58,317/78,953 
(73.86, 73.55-
74.17%) 
0.978 
Previous stroke 
(%, 95% CI) 
1,781/58,175 
(3.06, 2.92-
3.29%) 
2,177/65,134 
(3.34, 3.20-
3.48%) 
2,840/69,595 
(4.08, 3.93-
4.23%) 
2,917/71,897 
(4.06, 3.92-
4.20%) 
3,144/74,133 
(4.24, 4.09-
4.39%) 
3,187/77,341 
(4.12, 3.98-
4.26%) 
<0.001 
Previous 
valvular heart 
disease (%, 
95% CI) 
512/61,360 
(0.83, 0.76-
0.90%) 
583/66,254 
(0.88, 0.81-
0.95%) 
675/70,602 
(0.96, 0.89-
1.03%) 
831/73,083 
(1.14, 1.06-
1.22%) 
951/75,688 
(1.26, 1.18-
1.34%) 
1,177/79,055 
(1.49, 1.41-
1.57%) 
<0.001 
 
Receipt of 
circulatory 
support (%, 
95% CI) 
1,015/52,087 
(1.95, 1.83-
2.07%) 
1,131/60,784 
(1.86, 1.75-
1.97%) 
1,325/65,305 
(2.03, 1.92-
2.14%) 
1,510/68,388 
(2.21, 2.10-
2.32%) 
1,671/72,581 
(2.30, 2.19-
2.41%) 
1,741/76,530 
(2.27, 2.16-
2.38%) 
<0.001 
Thrombus 
aspiration (%, 
95% CI) 
1,032/52,989 
(1.95, 1.83-
2.07%) 
3,050/61,187 
(4.98, 4.81-
5.15%) 
6,864/66,536 
(10.32, 10.09-
10.55%) 
10,084/68,896 
(14.64, 14.38-
14.90%) 
11,937/72,237 
(16.52, 16.25-
16.79%) 
13,048/75,945 
(17.18, 16.91-
17.45%) 
<0.001 
Diagnosis 
Stable angina 
(%,95% CI) 
NSTEMI 
(%,95% CI) 
STEMI (%, 
95% CI) 
 
26,863 (46.77, 
46.36-47.18%) 
23,302 (40.57, 
40.17-40.97%) 
7,275 (12.67, 
12.40-12.94%) 
 
30,385 (46.64, 
46.26-47.02%) 
24,620 (37.79, 
37.42-38.16%) 
10,137 (15.56, 
15.28-15.84%) 
 
30,028 (42.79, 
42.42-43.16%) 
26,445 (37.68, 
37.32-38.04%) 
13,704 (19.53, 
19.24-19.82%) 
 
28,650 (39.44, 
39.08-39.80%) 
26,997 (37.17, 
36.82-37.52%) 
16,987 (23.39, 
23.08-23.70%) 
 
27,974 (37.15, 
36.80-37.50%) 
27,654 (36.73, 
36.39-37.07%) 
19,666 (26.12, 
25.81-26.43%) 
 
28,754 (36.49, 
36.15-36.83%) 
28,747 (36.48, 
36.14-36.82%) 
21,303 (27.03, 
26.72-27.34%) 
<0.001 
Haemorrhagic stroke 
Age (95% CI) 64.20 (64.11-
64.29) 
64.40 (64.31-
64.49) 
64.90 (64.81-
64.99) 
64.90 (64.81-
64.99) 
65.20 (65.11-
65.29) 
65.10 (65.02-
65.18) 
<0.001 
Previous 
valvular heart 
disease (%, 
95% CI) 
512/61,360 
(0.83, 0.76-
0.90%) 
583/66,254 
(0.88, 0.81-
0.95%) 
675/70,602 
(0.96, 0.89-
1.03%) 
831/73,083 
(1.14, 1.06-
1.22%) 
951/75,688 
(1.26, 1.18-
1.34%) 
1,177/79,055 
(1.49, 1.41-
1.57%) 
<0.001 
 
Diagnosis 
Stable angina 
(%,95% CI) 
NSTEMI 
(%,95% CI) 
STEMI (%, 
95% CI) 
 
26,863 (46.77, 
46.36-47.18%) 
23,302 (40.57, 
40.17-40.97%) 
7,275 (12.67, 
12.40-12.94%) 
 
30,385 (46.64, 
46.26-47.02%) 
24,620 (37.79, 
37.42-38.16%) 
10,137 (15.56, 
15.28-15.84%) 
 
30,028 (42.79, 
42.42-43.16%) 
26,445 (37.68, 
37.32-38.04%) 
13,704 (19.53, 
19.24-19.82%) 
 
28,650 (39.44, 
39.08-39.80%) 
26,997 (37.17, 
36.82-37.52%) 
16,987 (23.39, 
23.08-23.70%) 
 
27,974 (37.15, 
36.80-37.50%) 
27,654 (36.73, 
36.39-37.07%) 
19,666 (26.12, 
25.81-26.43%) 
 
28,754 (36.49, 
36.15-36.83%) 
28,747 (36.48, 
36.14-36.82%) 
21,303 (27.03, 
26.72-27.34%) 
<0.001 
Warfarin 445/51,290 
(0.87, 0.79-
0.95%) 
542/60,672 
(0.89, 0.82-
0.96%) 
662/66,027 
(1.00, 0.92-
1.08%) 
633/69,146 
(0.92, 0.85-
0.99%) 
657/72,468 
(0.91, 0.84-
0.98%) 
851/75,880 
(1.12, 1.05-
1.19%) 
<0.001 
Thrombolysis 4,701/50,769 
(9.26, 9.01-
9.51%) 
4,828/59,539 
(8.11, 7.89-
8.33%) 
4,108/64,633 
(6.36, 6.17-
6.55%) 
2,911/67,827 
(4.29, 4.14-
4.44%) 
1,329/69,981 
(1.90, 1.80-
2.00%) 
848/73,173 
(1.16, 1.08-
1.24%) 
<0.001 
*Oneway analysis of variance for continuous data. Chi
2
 test used to compare categorical data. 
 
Table 5: Risk of adverse outcomes with unadjusted, adjusted and imputed results for participants with ischaemic stroke/TIA and haemorrhagic 
stroke 
 
Variable No stroke Ischaemic 
stroke/TIA  
P-value Haemorrhagic stroke P-value 
MACE 
Unadjusted (n=426,190) 
Pseudo R
2
 
Adjusted model (n=227,100) 
Pseudo R
2
 
Adjusted model with imputation (n=360,500) 
 
1.00 (ref) 
 
1.00 (ref) 
 
1.00 (ref) 
 
8.34 (6.48-10.73) 
0.0018 
3.13 (1.84-5.30) 
0.0671 
3.03 (1.95-4.70) 
 
<0.001 
 
<0.001 
 
<0.001 
 
37.76 (25.83-55.21) 
0.0025 
13.19 (6.15-28.30) 
0.0675 
9.49 (4.93-18.27) 
 
<0.001 
<0.001 
<0.001 
30 day mortality 
Unadjusted (n=426,190) 
Pseudo R
2
 
Adjusted model (n=229,362) 
Pseudo R
2
 
Adjusted model with imputations (n=364,512)  
 
1.00 (ref) 
 
1.00 (ref) 
 
1.00 (ref) 
 
9.27 (7.18-11.99) 
0.0021 
4.94 (3.07-7.93) 
0.5012 
3.10 (2.02-4.75) 
 
<0.001 
 
<0.001 
 
<0.001 
 
44.16 (30.20-64.58) 
0.0030 
13.83 (6.35-30.12) 
0.5009 
10.14 (5.34-19.25) 
 
<0.001 
 
<0.001 
 
<0.001 
Adjusted model: adjusted for age, sex, smoking status, diabetes, hypertension, hypercholesterolaemia, previous MI, previous CVA, peripheral 
vascular disease, renal disease, previous valve disease, previous PCI, previous CABG, radial access site, cardiogenic shock, receipt of 
circulatory support, thrombus aspiration, ventilation, left main stem revascularization, diagnosis, glycoprotein IIb/IIIa, aspirin, clopidogrel, 
prasugrel, ticagrelor, ticlopidine, warfarin and thrombolysis 
Table 6: Propensity score matched simple logistic regression analyses with multiple imputation, odds of adverse outcomes*† 
Event Outcome Odds ratio (95% CI) p-value 
Ischaemic stroke/TIA  Mortality at 30 days 2.66 (1.97-3.60) <0.001 
MACE 2.54 (1.88-3.42) <0.001 
Haemorrhagic stroke Mortality at 30 days 4.08 (2.61-6.38) <0.001 
MACE 3.83 (2.45-5.98) <0.001 
Ischaemic stroke only Mortality at 30 days 2.79 (1.96-3.97) <0.001 
MACE 2.62 (1.84-3.72) <0.001 
TIA only Mortality at 30 days 1.85 (1.02-3.35) 0.042 
MACE 1.82 (1.03-3.24) 0.041 
* one to ten matching when possible (propensity score difference below 10
-5
) 
† Propensity score for ‘control’/’treatment’ groups calculated using age, sex, smoker, cardiogenic shock, diagnosis, previous MI, previous 
CABG, previous PCI, diabetes, year, left main stem, glycoprotein IIb/IIIa inhibitor use, circulatory support, hypercholesterolaemia, 
hypertension, previous stroke, valvular heart disease, renal disease, receipt of ventilation, aspirin use, clopidogrel use, warfarin use, prasugrel 
use, ticagrelor use, ticlopidine use, thrombus aspiration, femoral access and recent thrombolysis 
 
Supplementary Table 1: Patient characteristics for included participants and excluded 
participants 
Variable Included in analysis 
(n=426,297) 
Excluded from 
analysis (n=12,103) 
P-value 
Age 64.8 (±11.7) 64.8 (±11.7) 0.545 
Female 110,835/425,410 (74.0%) 8,771/12,044 (72.8%) 0.006 
Smoking 242,279/374,490 (64.7%) 6,404/10,272 (62.3%) <0.001 
Diabetes 76,909/407,703 (18.9%) 2,151/11,164 (19.3%) 0.283 
Hypertension 219,977/416,523 (52.8%) 4,757/9,127 (52.1%) 0.190 
Hyperlipidaemia 233,136/416,523 (56.0%) 4,555/9,127 (49.9%) <0.001 
Previous MI 107,055/380,039 (28.2%) 2,985/11,044 (27.0%) 0.009 
Previous CVA 16,056/416,523 (3.9%) 294/9,127 (3.2%) 0.002 
Peripheral 
vascular disease 
19,781/416,523 (4.8%) 476/9,127 (5.2%) 0.038 
Renal disease 10,805/403,697 (2.7%) 335/10,573 (3.2%) 0.002 
Previous valve 
disease 
4,733/426,293 (1.1%) 9/139 (6.5%) <0.001 
Previous PCI 90,659/408,933 (22.2%) 2,665/11,233 (23.7%) <0.001 
Previous CABG 34,398/407,887 (8.4%) 1,106/11,130 (9.9%) <0.001 
Access site 
Femoral 
Radial 
 
226,188 (56.0%) 
177,458 (44.0%) 
 
5,369 (47.3%) 
5,995 (52.8%) 
<0.001 
Cardiogenic 
shock 
8,095/398,035 (2.0%) 269/10,920 (2.5%) 0.002 
Use of 
circulatory 
support 
8,405/395,902 (2.1%) 312/9,812 (3.2%) <0.001 
Thrombus 
aspiration  
46,044/398,029 (11.6%) 1,500/10,822 (13.9%) <0.001 
Ventilatory 
support 
4,924/355,928 (1.4%) 158/9,816 (1.6%) 0.059 
Left Main Stem 13,176/412,350 (3.2%) 396/9,818 (4.0%) <0.001 
Diagnosis 
Stable angina 
NSTEMI 
STEMI 
 
172,745 (41.2%) 
157,871 (37.6%) 
89,118 (21.2%) 
 
4,647 (38.9%) 
4,381 (36.7%) 
2,921 (24.5%) 
<0.001 
Glycoprotein 
IIb/IIIa 
88,269/373,396 (23.6%) 1,929/8,572 (22.5%) 0.014 
Aspirin 330,610/395,728 (83.5%) 8,302/9,252 (89.7%) <0.001 
Clopidogrel 305,475/395,728 (77.2%) 7,077/9,252 (76.5%) 0.112 
Prasugrel 13,498/395,728 (3.4%) 579/9,252 (6.3%) <0.001 
Ticagrelor 2,784/395,728 (0.7%) 247/9,252 (2.7%) <0.001 
Ticlopidine 1,364/395,728 (0.3%) 54/9,252 (0.6%) <0.001 
Warfarin 3,792/395,728 (1.0%) 101/9,252 (1.1%) 0.194 
Thrombolysis 18,739/386,154 (4.9%) 476/10,689 (4.5%) 0.058 
30-day mortality 8,724/426,297 (2.1%) 244/12,103 (2.0%) 0.816 
 
 Supplementary Table 2: Included and missing data 
Variable Included in analysis Missing  
Stroke type 426,436 (97.3%) 11,964 (2.7%) 
Age 438,136 (99.9%) 264 (0.1%) 
Gender 437,454 (99.8%) 946 (0.2%) 
Smoking status 384,762 (87.8%) 53,638 (12.2%) 
Diabetes 418,867 (95.5%) 19,533 (4.5%) 
Hypertension 425,650 (97.1%) 12,750 (2.9%) 
Hypercholesterolaemia 425,650 (97.1%) 12,750 (2.9%) 
Previous myocardial 
infarction 
391,083 (89.2%)  47,317 (10.8%) 
Previous stroke 425,650 (97.1%) 12,750 (2.9%) 
Peripheral vascular disease 425,650 (97.1%) 12,750 (2.9%) 
Renal disease 414,270 (94.5%) 24,130 (5.5%) 
Valvular heart disease 426,432 (97.3%) 11,968 (2.7%) 
Previous PCI 420,166 (95.8%) 18,234 (4.2%) 
Previous CABG 419,017 (95.6%) 19,383 (4.4%) 
Access site 415,010 (94.7%) 23,390 (5.3%) 
Cardiogenic shock 408,955 (93.3%) 29,445 (6.7%) 
Circulatory support 405,714 (92.5%) 32,686 (7.5%) 
Thrombus aspiration 408,851 (93.3%) 29,549 (6.7%) 
Ventilatory support 365,744 (83.4%) 72,656 (16.6%) 
Left main stem disease 422,168 (96.3%) 16,232 (3.7%) 
Diagnosis 431,683 (98.5%) 6,717 (1.5%) 
Glycoprotein IIb/IIIa 
inhibitor use 
381,968 (87.1%) 56,432 (12.9%) 
Aspirin use 404,980 (92.4%) 33,420 (7.6%) 
Clopidogrel use 404,980 (92.4%) 33,420 (7.6%) 
Prasugrel use 404,980 (92.4%) 33,420 (7.6%) 
Ticagrelor use 404,980 (92.4%) 33,420 (7.6%) 
Ticlopidine use 404,980 (92.4%) 33,420 (7.6%) 
Warfarin use 404,980 (92.4%) 33,420 (7.6%) 
Thrombolysis use 396,843 (90.5%) 41,557 (9.5%) 
MACE 426,575 (96.3%) 11,825 (2.7%) 
30 day mortality 438,400 (100%) 0 (0%) 
PCI=percutaneous coronary intervention, CABG=coronary artery bypass graft 
Supplementary Table 3: Missing data by year of procedure 
Variable 2007 (n=63,437) 2008 (n=68,285) 2009 (n=71,716) 2010 (n=75,044) 2011 (n=78,376) 2012 (n=81,542) 
Age 47 (0.07%) 31 (0.05%) 33 (0.05%) 74 (0.10%) 58 (0.07%) 21 (0.03%) 
Gender 178 (0.38%) 70 (0.10%) 77 (0.11%) 158 (0.21%) 361 (0.46%) 102 (0.13%) 
Smoking status 11,801 (18.60%) 9,703 (14.21%) 7,616 (10.62%) 8,366 (11.15%) 7,997 (10.20%) 8,155 (10.00%) 
Diabetes 4,685 (7.39%) 2,817 (4.13%) 2,058 (2.87%) 2,688 (3.58%) 2,899 (3.70%) 4,386 (5.38%) 
Hypertension 4,329 (6.82%) 1,917 (2.81%) 1,227 (1.71%) 1,339 (1.78%) 1,976 (2.52%) 1,962 (2.41%) 
Hypercholesterolaemia 4,329 (6.82%) 1,917 (2.81%) 1,227 (1.71%) 1,339 (1.78%) 1,976 (2.52%) 1,962 (2.41%) 
Previous myocardial 
infarction 
10,623 (16.75%) 9,690 (14.19%) 8,067 (11.25%) 6,710 (8.94%) 6,044 (7.71%) 6,183 (7.58%) 
Previous stroke 4,329 (6.82%) 1,917 (2.81%) 1,227 (1.71%) 1,339 (1.78%) 1,976 (2.52%) 1,962 (2.41%) 
Peripheral vascular 
disease 
4,329 (6.82%) 1,917 (2.81%) 1,227 (1.71%) 1,339 (1.78%) 1,976 (2.52%) 1,962 (2.41%) 
Renal disease 6,580 (10.37%) 3,659 (5.36%) 2,548 (3.55%) 3,766 (5.02%) 3,871 (4.94%) 3,706 (4.54%) 
Valvular heart disease 2,016 (3.18%) 1,964 (2.88%) 1,065 (1.49%) 1,865 (2.49%) 2,613 (3.33%) 2,445 (3.00%) 
Previous PCI 6,219 (9.80%) 3,606 (5.28%) 2,462 (3.43%) 1,749 (2.33%) 2,012 (2.57%) 2,186 (2.68%) 
Previous CABG 5,248 (8.27%) 3,607 (5.28%) 3,363 (4.69%) 2,857 (3.81%) 2,436 (3.11%) 1,872 (2.30%) 
Access site 5,236 (8.25%) 4,492 (6.58%) 2,989 (4.17%) 3,425 (4.56%) 3,508 (4.48%) 3,740 (4.59%) 
Cardiogenic shock 8,065 (12.71%) 4,610 (6.75%) 4,277 (5.96%) 4,152 (5.53%) 4,421 (5.64%) 3,920 (4.81%) 
Circulatory support 9,867 (15.55%) 5,632 (8.25%) 5,413 (7.55%) 4,963 (6.61%) 3,369 (4.30%) 3,442 (4.22%) 
Thrombus aspiration 8,448 (13.32%) 5,107 (7.48%) 4,111 (5.73%) 4,311 (5.74%) 3,674 (4.69%) 3,898  (4.78%) 
Ventilatory support 16,319 (25.72%) 15,368 (21.04%) 11,692 (16.30%) 11,036 (14.71%) 9,898 (12.63%) 9,343 (11.46%) 
Left main stem disease 4,964 (7.83%) 2,395 (3.51%) 1,923 (2.68%) 2,673/75,044 
(3.56%) 
2,079 (2.65%) 2,198 (2.70%) 
Diagnosis 3,939 (6.21%) 1,130 (1.65%) 447 (0.62%) 462 (0.62%) 425 (0.54%) 314 (0.39%) 
Glycoprotein IIb/IIIa 
inhibitor use 
11,147 (17.57%) 9,445 (13.83%) 9,094 (12.12%) 9,094 (12.12%) 9,240 (12.12%) 9,240 (11.79%) 
Aspirin use 10,807 (17.04%) 6,086 (8.91%) 4,698 (6.55%) 4,169 (5.56%) 3,935 (5.02%) 3,725 (4.57%) 
Clopidogrel use 10,807 (17.04%) 6,086 (8.91%) 4,698 (6.55%) 4,169 (5.56%) 3,935 (5.02%) 3,725 (4.57%) 
Prasugrel use 10,807 (17.04%) 6,086 (8.91%) 4,698 (6.55%) 4,169 (5.56%) 3,935 (5.02%) 3,725 (4.57%) 
Ticagrelor use 10,807 (17.04%) 6,086 (8.91%) 4,698 (6.55%) 4,169 (5.56%) 3,935 (5.02%) 3,725 (4.57%) 
Ticlopidine use 10,807 (17.04%) 6,086 (8.91%) 4,698 (6.55%) 4,169 (5.56%) 3,935 (5.02%) 3,725 (4.57%) 
Warfarin use 10,807 (17.04%) 6,086 (8.91%) 4,698 (6.55%) 4,169 (5.56%) 3,935 (5.02%) 3,725 (4.57%) 
Thrombolysis use 10,690 (16.85%) 6,837 (10.01%) 6,099 (8.50%) 5,360 (7.14%) 5,945 (7.59%) 6,626 (8.13%) 
MACE 2,008 (3.17%) 1,951 (2.86%) 1,037 (1.45%) 1.832 (2.44%) 2,585 (3.30%) 2,412 (2.96%) 
30 day mortality 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
PCI=percutaneous coronary intervention, CABG=coronary artery bypass graft 
Supplementary Table 4: Stroke and TIA events by year of PCI 
Stroke/TIA type 2007 2008 2009 2010 2011 2012 Total 
Ischaemic 
stroke/TIA 
Events/1000 
patients (95% 
CI) 
41/61,387 
(0.067%) 
0.67 (0.47-0.87) 
52/66,267 
(0.078%) 
0.78 (0.58-0.98) 
77/70,608 
(0.109%) 
1.09 (0.89-1.29) 
85/73,132 
(0.116%) 
1.16 (0.96-1.36) 
91/75,734 
(0.120%) 
1.20 (1.00-1.40) 
90/79,062 
(0.114%) 
1.14 (0.94-1.34) 
436/426,190 
(0.102%) 
1.02 (0.92-1.12) 
Haemorrhagic 
stroke 
Events/1000 
patients (95% 
CI) 
18/61,364 
(0.029%) 
0.29 (0.19-0.39) 
22/66,237 
(0.033%) 
0.33 (0.23-0.43) 
25/70,556 
(0.035%) 
0.35 (0.25-0.45) 
22/73,069 
(0.030%) 
0.30 (0.20-0.40) 
8/75,651 
(0.011%) 
0.11 (0.01-0.21) 
12/78,984 
(0.015%) 
0.15 (0.05-0.25) 
107/425,861 
(0.025%) 
0.25 (0.20-0.30) 
Ischaemic stroke 
Events/1000 
patients (95% 
CI) 
20/61,366 
(0.033%) 
0.33 (0.23-0.43) 
33/66,248 
(0.050%) 
0.50 (0.30-0.70) 
38/70,569 
(0.054%) 
0.54 (0.34-0.74) 
62/73,109 
(0.085%) 
0.85 (0.65-1.05) 
49/75,692 
(0.065%) 
0.65 (0.45-0.85) 
59/79,031 
(0.075%) 
0.75 (0.55-0.95) 
261/426,015 
(0.061%) 
0.61 (0.51-0.71) 
TIA 
Events/1000 
patients (95% 
CI) 
21/61,367 
(0.034%) 
0.34 (0.24-0.44) 
19/66,234 
(0.029%) 
0.29 (0.19-0.39) 
39/70,570 
(0.055%) 
0.55 (0.35-0.75) 
23/73,070 
(0.031%) 
0.31 (0.21-0.41) 
42/75,685 
(0.055%) 
0.55 (0.35-0.75) 
31/79,003 
(0.039%) 
0.39 (0.29-0.49) 
175/425,929 
(0.041%) 
0.41 (0.31-0.51) 
 
Supplementary Table 5: Crude adverse event rates by stroke/TIA group 
Group MACE Mortality at 30 days 
Ischaemic stroke/TIA 
Yes 
No 
 
 
73/436 (17%) 
10,026/425,754 (2%) 
 
70/436 (16%) 
8,603/425,754 (2%) 
Haemorrhagic stroke 
Yes 
No 
 
51/107 (48%) 
10,026/425,754 (2%) 
 
51/107 (48%) 
8,603/425,754 (2%) 
Ischaemic stroke 
Yes 
No 
 
57/261 (22%) 
10,026/425,754 (2%) 
 
55/261 (21%) 
8,603/425,754 (2%) 
TIA 
Yes 
No 
 
16/175 (9%) 
10,026/425,754 (2%) 
 
15/175 (9%) 
8,603/425,754 (2%) 
 
 
 
 
Supplementary Table 6: Risk of adverse outcomes with unadjusted, adjusted and imputed results for participants in ischaemic stroke and TIA 
 
Variable No stroke Ischaemic stroke P-value TIA P-value 
MACE 
Unadjusted (n=426,015) 
Pseudo R
2
 
Adjusted model (n=226,999) 
Pseudo R
2
 
Adjusted model with imputation (n=360,350) 
 
1.00 (ref) 
 
1.00 (ref) 
 
1.00 (ref) 
 
11.59 (8.63-15.55) 
0.0017 
3.16 (1.65-6.07) 
0.0667 
3.11 (1.79-5.39) 
 
<0.001 
 
<0.001 
 
<0.001 
 
4.17 (2.49-6.98) 
0.0002 
3.07 (1.26-7.48) 
0.0665 
2.91 (1.40-6.02) 
 
<0.001 
 
0.014 
 
0.004 
30 day mortality 
Unadjusted (n=426,015) 
Pseudo R
2
 
Adjusted model (n=229,255) 
Pseudo R
2
 
Adjusted model with imputations (n=364,356) 
 
1.00 (ref) 
 
1.00 (ref) 
 
1.00 (ref) 
 
12.95 (9.61-17.45) 
0.0020 
4.79 (2.68-8.57) 
0.5008 
3.32 (1.98-5.56) 
 
<0.001 
 
<0.001 
 
<0.001 
 
4.55 (2.68-7.72) 
0.0003 
5.24 (2.32-11.81) 
0.4997 
2.69 (1.25-5.77) 
 
<0.001 
 
<0.001 
 
0.011 
Adjusted model: adjusted for age, sex, smoking status, diabetes, hypertension, hypercholesterolaemia, previous MI, previous CVA, peripheral vascular 
disease, renal disease, previous valve disease, previous PCI, previous CABG, radial access site, cardiogenic shock, receipt of circulatory support, thrombus 
aspiration, ventilation, left main stem revascularization, diagnosis, glycoprotein IIb/IIIa, aspirin, clopidogrel, prasugrel, ticagrelor, ticlopidine, warfarin and 
thrombolysis
Supplementary Table 7: Propensity scores for comparison groups*† 
Event Mean Standard 
Deviation 
Ischaemic stroke/TIA  No 0.00107 0.00168 
Yes 0.00311 0.00418 
Haemorrhagic stroke No 0.00027 0.00126 
Yes 0.00557 0.01243 
Ischaemic stroke only No 0.00064 0.00139 
Yes 0.00307 0.00535 
TIA only No 0.00043 0.00048 
Yes 0.00090 0.00083 
* Propensity score for ‘control’/’treatment’ groups calculated using age, sex, smoker, cardiogenic 
shock, diagnosis, previous MI, previous CABG, previous PCI, diabetes, year, left main stem, 
glycoprotein IIb/IIIa inhibitor use, circulatory support, hypercholesterolaemia, hypertension, previous 
stroke, valvular heart disease, renal disease, receipt of ventilation, aspirin use, clopidogrel use, 
warfarin use, prasugrel use, ticagrelor use, ticlopidine use, thrombus aspiration, femoral access and 
recent thrombolysis 
† Across the 10 datasets used in the multiple imputation processes 
 
